CMS has embarked on a national coverage determination process, in which it’s examining the clinical safety and benefit profile of Aduhelm and other anti beta amyloid monoclonal antibodies in Alzheimer’s patients. As CMS decides whether to pay for Aduhelm its future success is uncertain.
As Medicare Decides Whether To Pay For Aduhelm To Treat Alzheimer’s Disease, Its Future Is Uncertain
